Shrushma Loi

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019, The Lancet.

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

C. Caldas, J. Abraham, H. Earl, 2018 .

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

C. Caldas, E. Provenzano, J. Abraham, 2020, Health technology assessment.

Trastuzumab-associated cardiac events in the Persephone trial

J. Abraham, H. Earl, D. Miles, 2016, British Journal of Cancer.